Cite

    Xu, Z. et al. (2023). Comparing the bioequivalence and safety of liraglutide in healthy Chinese subjects: an open, single-dose, randomized, repeated, two-sequence, two-cycle phase I clinical trial. Expert review of clinical pharmacology. 16 (4), pp. 363-370. [Online].